Amanda Heslegrave, PhD, University College London, London, UK, discusses the challenges in implementing a blood-based biomarker assessment for Alzheimer’s disease diagnosis. A fast and accurate screening solution could improve detection rates and reduce pressure on specialized services, helping to address current underdiagnosis issues in the UK. It is clear that early diagnosis is key to optimizing management and maximizing the potential of therapeutic interventions. As well as establishing the capacity to conduct large volumes of tests, education of front-line professionals on how and when to use the tests and how to advise their patients is key. The introduction of a biomarker test would also raise ethical issues, given the current lack of treatment options and potential future access issues if the costly treatments recently approved in the US are introduced in the UK. This interview took place at the Alzheimer’s Research UK (ARUK) Conference 2023 in Aberdeen, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
